Markets:

Overview

News

Currencies

International

Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

4.485 -0.365 (-7.53%)

Streaming Delayed Price Updated: 3:46 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

3 Cash-Burning Stocks Facing Headwinds

May 30, 2025

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.

Via StockStory

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 27, 2025

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators

From Myriad Genetics, Inc.

Via GlobeNewswire

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

May 26, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.

Via StockStory

Topics Artificial Intelligence

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Myriad Genetics's Earnings: A Preview ↗

May 05, 2025

Via Benzinga

3 Small-Cap Stocks with Questionable Fundamentals

May 22, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday ↗

May 21, 2025

Via Benzinga

CI&T, Novavax, Paramount Group And Other Big Stocks Moving Higher On Monday ↗

May 19, 2025

Via Benzinga

MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp

May 19, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year...

Via StockStory

Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

May 14, 2025

Correction: Time of BofA Conference

From Myriad Genetics, Inc.

Via GlobeNewswire

3 of Wall Street’s Favorite Stocks in Dangerous Territory

May 12, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

May 08, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

May 08, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullish ↗

May 07, 2025

Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges.

Via Stocktwits

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

May 07, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

What Analysts Are Saying About Myriad Genetics Stock ↗

May 07, 2025

Via Benzinga

Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

May 07, 2025

Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk

From Myriad Genetics, Inc.

Via GlobeNewswire

Top movers in Wednesday's session ↗

May 07, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Why Myriad Genetics (MYGN) Stock Is Down Today

May 07, 2025

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS, and...

Via StockStory

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 07, 2025

Via Benzinga

Crude Oil Falls 1%; Uber Sales Miss Estimates ↗

May 07, 2025

Via Benzinga

Topics Earnings

Wednesday's session: top gainers and losers ↗

May 07, 2025

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

May 07, 2025

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

These stocks that are showing activity before the opening bell on Wednesday. ↗

May 07, 2025

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 07, 2025

Via Benzinga

Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%

May 06, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue...

Via StockStory

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 06, 2025

Via Benzinga

Which stocks are moving after the closing bell on Tuesday? ↗

May 06, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

May 06, 2025

From Myriad Genetics, Inc.

Via GlobeNewswire

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

May 05, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.